Oct 28, 4:08 PM ET
CONMED reported third quarter 2026 net sales of $335.6 million, down 0.7% from a year earlier, and adjusted diluted EPS of $1.04, down 3.2%. GAAP diluted EPS was $0.66, up from $0.09, and the company updated its full year 2026 guidance to net sales of $1,360 million to $1,366 million and adjusted diluted EPS of $4.54 to $4.61. The picture is mixed for shareholders: the adjusted EPS range moved higher, while the top end of the sales range was lowered.
- Third quarter net sales were $335.6 million, down 0.7%; excluding GI product offering exits, organic constant currency net sales grew 6.7%.
- Domestic sales fell 11.0% as reported, while international sales rose 13.1% as reported.
- Full year 2026 net sales guidance is $1,360 million to $1,366 million, versus prior guidance of $1,358 million to $1,373 million.
- Full year 2026 adjusted diluted EPS guidance is $4.54 to $4.61, versus prior guidance of $4.48 to $4.60.
Read the filing on SEC.gov ↗
Jul 29, 4:10 PM ET
CONMED reported second quarter 2026 net sales of $343.5 million, up 0.3% as reported and down 0.5% on a constant currency basis, with GAAP diluted EPS of $0.77 and adjusted diluted EPS of $1.38. The company raised its full year 2026 adjusted diluted EPS guidance to $4.48 to $4.60 from $4.30 to $4.45, and narrowed its net sales guidance to $1,358 million to $1,373 million from $1,350 million to $1,375 million.
- Q2 2026 net sales $343.5 million, up 0.3% as reported; domestic sales down 8.0% and international sales up 10.8%
- GAAP diluted EPS $0.77, up 11.6%; adjusted diluted EPS $1.38, up 20.0%, both including a $0.21 benefit from IEEPA tariff refunds
- Full year 2026 adjusted diluted EPS guidance raised to $4.48 to $4.60 from $4.30 to $4.45
- Full year 2026 net sales guidance $1,358 million to $1,373 million, versus prior $1,350 million to $1,375 million
Read the filing on SEC.gov ↗
Jun 17, 4:49 PM ET
CONMED Corporation appointed John E. Gallagher as Executive Vice President and Chief Financial Officer, effective July 15, 2026, succeeding Todd Garner, who remains with the company in an advisory role through November 2, 2026. Gallagher's pay includes a $650,000 base salary, a bonus target of 85% of base salary, and equity grants under the 2025 Long-Term Incentive Plan, which are subject to Compensation Committee approval.
- Gallagher previously served as CFO of Certara, Inc. from April 2023 and as CFO of Cue Health Inc. from 2021 to 2023.
- Annual base salary is $650,000, with an annual cash bonus targeted at 85% of base salary.
- Equity grants include options with a $575,000 grant value, restricted stock units worth $1,150,000 plus $1,500,000, and performance stock units worth $575,000, subject to Compensation Committee approval.
- Patrick Beyer stops serving as interim principal financial officer on the effective date and remains President and CEO.
Read the filing on SEC.gov ↗
Jun 4, 7:30 AM ET
On June 3, 2026, CONMED agreed in privately negotiated purchase agreements with certain holders to buy about $645.2 million of its 2.25% Convertible Senior Notes due 2027 for about $637.2 million in cash. The transactions are expected to close on June 15, 2026, subject to customary closing conditions, and would reduce the company's outstanding convertible debt.
- Principal amount of notes to be purchased: approximately $645.2 million of 2.25% Convertible Senior Notes due 2027
- Cash consideration: approximately $637.2 million
- Agreements dated June 3, 2026, with certain holders of the notes in privately negotiated transactions
- Expected closing date: June 15, 2026, subject to customary closing conditions
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.